(Treffer aus pharmind, Nr. 11, Seite 1580 (2016))
Sinner A | Braun U | Rehm A
Supply Chain Management / Part 3: Creating Value – For and Around the Patient
Part 1 see Pharm Ind. 2015;77(10):1452–1457; Part 2 see Pharm Ind. 2016;78(9):1270–1275. · Sinner A, Braun U, Rehm A · 1
Camelot Management Consultants AG, Mannheim und 2
Schreiner MediPharm, Oberschleißheim
Some years ago, the pharmaceutical industry was shocked by changing market conditions, such as the German AMNOG influence in the overall European market and increased demand for proof of real-world evidence of the treatment with new medications in the US. At the same time, many pharmaceutical companies were facing patent cliffs. In fact, the overall business model of innovative pharma was questioned for a while. A changed mindset led to the introduction of new products which have either provided additional benefits or are expected to show such benefits in the real world. As more pharma companies realize improved outcomes with ...